2022 / 01

Next Paper
DOI: 10.24075/medet.2022.036

REVIEW

The issues of classification and characterization of neurotropic agents in the treatment of patients with cerebrovascular diseases

Fedorov VN1, Petrovskii AK2, Vdovichenko VP3, Zakharova MN2, Arshinov AV2
About authors

1 Yaroslavl State Pedagogical University named after K. D. Ushinsky, Yaroslavl, Russia

2 Yaroslavl State Medical University, Yaroslavl, Russia

3 State Medical University of Grodno, Grodno, Republic of Belarus

Correspondence should be addressed: Vladimir N. Fedorov
ul. Technoparkovaya, 11/2, Yaroslavl, 150000, Russia; moc.liamtoh@rimidalv.vrodef

About paper

Author contribution: Fedorov VN — concept and design development, article editing, responsibility for proper presentation of the issues related to consistency of data and integrity of all parts; Petrovskii AK — collection and primary treatment of data; Vdovichenko VP — collection, analysis and interpretation of data; Zakharova MN — arranging references by order of their mentioning in the text; Arshinov AV — initial writing and language presentation of the text.

Received: 2022-01-20 Accepted: 2022-02-26 Published online: 2022-03-30
|
  1. Hasanova LT. Geneticheskie faktory razvitiya insul’ta. RMZH. 2019; (7): 34–36. Russian.
  2. Ivanova GE. Innovacii v reabilitacii bol’nyh posle insul’ta na ambulatornom etape. RMZH. 2019; (4): 100–104. Russian.
  3. Kostenko EV, Petrova LV. Patofiziologicheskie osobennosti hronicheskih cereb-r ovaskulyarnyh zabolevanij i vozmozhnosti kompleksnoj nejroprotektivnoj terapii. Medicinskij sovet. 2019; (1): 24–30. Russian.
  4. Tabeeva GR. Rol’ cerebrovaskulyarnoj patologii v razvitii demencii smeshannogo geneza. RMZH. 2018; (12): 16–20. Russian.
  5. Dichgans M, Leys D. Vascular cognitive impairment. Circulation research. 2017; 120 (3): 573–591.
  6. Boursin P, Paternotte S, Dercy B, et al. Semantics, epidemiology and semiology of stroke. Soins. 2018; 63 (828): 24–27.
  7. Smith EE. Clinical presentations and epidemiology of vascular dementia. Clin Sci. 2017; 131 (11): 1059–1068.
  8. Rachin AP, Tynterova AM, Nuvahova MB, Rachin SA. Nejropeptidnaya terapiya ko-gnitivnyh rasstrojstv na fone hronicheskoj ishemii golovnogo mozga. Medical Review. 2019; (4): 87–90. Russian.
  9. Vorob’eva OV. Hronicheskaya ishemiya golovnogo mozga: ot patogeneza k terapii (reko-mendacii nevrologu ambulatornogo zvena). RMZH. 2018; (5): 26–31. Russian.
  10. Vygovskaya SN, Nuvahova MB, Doroginina AY, Rachin AP. Hronicheskaya ishemiya golovnogo mozga — ot pravil’noj diagnostiki k optimal’noj terapii. RMZH. 2015; (12): 664–668. Russian.
  11. Karsy M, Brock A, Guan J, Taussky P. Neuroprotective strategies and the underlying molecular basis of cerebrovascular stroke. Neurosurg Focus. 2017; 42 (4): 3.
  12. Reis C, Akyol O, Ho WM, Araujo C, Huang L, Applegate JH. Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. Biomed Res Int. 2017; 2017: 4863079.
  13. Smetneva NS, Goloborodova IV, Popkova AM, Samojlova NV, Igonina NP, Shatrova GV. Terapiya kognitivnyh narushenij pri hronicheskoj ishemii golovnogo mozga v obshchevrachebnoj praktike. RMZH. 2018; (7): 15–22. Russian.
  14. Pires PW, Dams Ramos CM, Matin N, Dorrance AM. The effects of hypertension on the cerebral circulation. Am J Physiol Heart Circ Physiol. 2013; 304 (12): 1598–1614.
  15. Zozulya IS, Martynyuk VYu, Majstruk OA. Nejroprotektory, nootropy, nejrome- tabolity v intensivnoj terapii porazhenij nervnoj sistemy. Kiev: Intermed. 2005; 132 s. Russian.
  16. Cygan VN, Gurskaya OE, Il’inskij NS. Etiopatogeneticheskaya nejroreparativnaya terapiya encefalopatij. Vestnik Rossijskoj voenno- medicinskoj akademii. 2018; (1): 139–144. Russian.
  17. Titova NV. Sovremennyj vzglyad na nootropnuyu terapiyu. RMZH. 2007; (24): 1846–1851. Russian.
  18. Evtushenko IS. Nootropy i nejroprotektory s sovremennoj klinicheskoj nejrofar- makologii. Mezhdunarodnyj nevrologicheskij zhurnal. 2015; (32): 20–27. Russian.
  19. Gusev EI, Skvorcova VI, Platonova IA. Terapiya ishemicheskogo insul’ta. Consilium medicum. 2012; (24): 56–60. Russian.
  20. Chimagomedova ASh, Levin OS, Skripkina NA, Gutorova DA, Vasenina EE. Voz-mozhnosti primeneniya memantina v rannej terapii postinsul’tnoj demencii. RMZH. 2017; (21): 1512–1517. Russian.
  21. Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomized, placebo–controlled trial (MMM 300). Stroke. 2002; (33): 1834–1839.
  22. Foo K, Blumenthal L, Man HY. Regulation of neuronal bioenergy homeostasis by glutamate. Neurochem Int. 2012; 61 (3): 389– 396.
  23. Kamchatnov PR, Mihajlova NA, ZHdanova SV. Korrekciya svobodnoradikal’nogo okis-leniya u bol’nyh s rasstrojstvami mozgovogo krovoobrashcheniya. Trudnyj pacient. 2010; 8 (6–7): 26–33.
  24. Mashin VV, Belova VA, Dudikov EM, Bergel’son TM, Lankov VA, Zakuraeva KA. Effektivnost’ preparata rekognan u pacientov v ostrom periode ishemicheskogo in-sul’ta. ZHurnal nevrologii i psihiatrii im. C. C. Korsakova. 2017; (10): 44–48.
  25. Okovityj SV. Klinicheskaya farmakologiya antigipoksantov (chast’ I). Sankt- Peterburg: FARMindeks- Praktik. 2004; 72 s.
  26. Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha- glycerylphosphoryl-choline) an old choline-c ontaining phospholipid with a still interesting profile as cognition enhancing agent. Curr. Alzheimer Res. 2013; 10 (10): 1070–1079.
  27. Secades JJ Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol. 2016; 63 (03): 1–73.
  28. Ponto LL, Schultz SK. Ginkgo biloba extract: Review of CNS effects. Ann Clin Psych. 2003; (15): 109–119.
  29. Cisneros- Mejorado A, Gottlieb M, Ruiz A, Chara JC. Blockade and knock-out of CALHM1 channels attenuate ischemic brain damage. J Cereb Blood Flow Metab. 2017:271678X17713587.
  30. Stepanichev M, Onufriev M, Aniol V, et al. Effects of cerebrolysin on nerve growth factor system in the aging rat brain. Restorative Neurology and Neuroscience. 2017; 35 (6): 571–581.
  31. D’yakonov MM, SHabanov PD. K voprosu o nejroprotektivnom dejstvii peptidnyh preparatov. Vestnik Rossijskoj Voenno- medicinskoj akademii. 2011; 1(33): 23–28. Russian.
  32. Kovalyov GI. Rol’ receptornogo komponenta v nejrohimicheskom mekhanizme dejstviya Pantogama i Pantogam aktiva. V kn.: Pantogam® i Pantogam aktiv®. Klinicheskoe primenenie i fundamental’nye issledovaniya./pod red. V. M. Kopelevicha. M.: Triada–farm. 2009; 129–139. Russian.
  33. Duma SN. Ocenka klinicheskoj effektivnosti nejroprotektorov, vliyayushchih na sistemu gamma-a minomaslyanoj kisloty, pri lechenii kognitivnyh rasstrojstv u pacientov s discirkulyatornoj encefalopatiej I–II stadij. Farmateka. 2010; (15): 96–100. Russian.
  34. Shahparonova NV, Kadykov AS. Nejrometabolicheskaya terapiya bol’nyh s zabolevaniyami nervnoj sistemy. Vozmozhnosti primeneniya Aktovegina. RMZH. 2008; (26): 1722–1727. Russian.
  35. Gimoyan LG, Silvanyan GG. Primenenie mildronata v lechenii kognitivnyh narushenij pri sosudistoj demencii. RMZH. 2017; (21): 1518–1524. Russian.
  36. Zhu Y, Zhang G, Zhao J, et al. Efficacy and safety of mildronate for acute ischemic stroke: a randomized, double- blind, active- controlled phase II multicenter trial. Clin Drug Investig. 2013; 33(10): 755–760.
  37. Chiechio S, Canonico P, Grilli M. L-Acetylcarnitine: A Mechanistically Distinctive and Potentially Rapid- Acting Antidepressant Drug. Int J Mol Sci. 2018; 19 (11): 11–13;
  38. Li S, Chen X, Li Q, et al. Effects of acetyl- L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-b lind, controlled trial. J Diabetes Investig. 2016; (7): 777–785.
  39. Montenegro L, Turnaturi R, Parenti C, Pasquinucci L. Idebenone: Novel Strategies to Improve Its Systemic and Local Efficacy. Nanomaterials (Basel). 2018; 8 (2): 122–134.
  40. Jaber S, Polster BM. Idebenone and Neuroprotection: Antioxidant, Pro-oxidant, or Electron Carrier? J Bioenerg. Biomembr. 2015; (47): 111–118.
  41. Fadda LM, Hagar H, Mohamed AM, Ali HM. Quercetin and Idebenone Ameliorate Oxidative Stress, Inflammation, DNA damage, and Apoptosis Induced by Titanium Dioxide Nanoparticles in Rat Liver. Dose Response. 2018; 16 (4): 1559.
  42. Winblad B. Piracetam: A review of pharmacological properties and clinical uses. CNS Drug Rev. 2008; (11): 169–182.
  43. Sychev DA, Gerasimova KV, Otdelenov VA. Piracetam i piracetamopodobnye preparaty: vzglyad klinicheskogo farmakologa. RMZH. 2012; (15): 957. Russian.
  44. CHernij TV, Andronova IA, CHernij VI, Gorodnik GA. Algoritm podbora effektivnoj i bezopasnoj dozy vvedeniya Tiocetama na gospital’nom etape lecheniya ostroj cerebral’noj nedostatochnosti. Medicina neotlozhnyh sostoyanij. 2010; 1 (26). Russian.
  45. Myasoedov NF. Innovacionnye lekarstva: ot fundamental’nyh issledovanij k proizvodstvu. Vestnik Rossijskoj akademii nauk. 2016; (6): 488–494. Russian.
  46. Budni J, Bellettini- Santos T, Mina F, et al. The involvement of BDNF, NGF and GDNF in aging and Alzheimer’s disease. Aging and Diseases. 2015; 6 (5): 331–341.
  47. Kolomin Т, Shadrina M, Slominsky Р, Limborska S, Myasoedov N. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuro-science & Medicine. 2013; (4): 223–252.
  48. Xuejuan Z, Gareth L, Jianfeng F. Coherent peptide-m ediated activity in a neuronal network controlled by subcellular signaling pathway: Experiments and modeling. Journal of Biotechnology. 2010; (149): 215–225.
  49. Firstova YY, Dolotov OV, Kondrahin EA, Dubynina EV, Grivennikov IA, Kovalev GI. Vliyanie nootropnyh preparatov na uroven’ BDNF v gippokampe i kore mozga myshej s razlichnoj effektivnost’yu issledovatel’skogo povedeniya. Eksper i klin farmakol. 2009; (6): 3–6. Russian.
  50. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006; (1): 54–60. Russian.
  51. Bezuglov VV, Akimov MG, Gretskaya NM, et al. The Study of the Neurotropic Peptides Role in Cell Responses Regulation. Horizons in Neuroscience Research. 2015; (21): 151–170.
  52. Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: Genome-wide transcriptional analysis. BMC Genomics. 2014; 15(1): 1–12.
  53. Polyakova AV. Nejroprotektivnaya terapiya vne «terapevticheskogo okna»: vozmozhnosti semaksa. Vestnik nevrologii, psihiatrii i nejrohirurgii. 2014; (5): 54–60. Russian.
  54. Dubynina EV, Dolotov OV. Transkripcionnyj faktor CREB i processy formirovaniya pamyati. Nejrohimiya. 2009; (3): 181–190. Russian.
  55. Aubekova O.M, Klimova EA. Terapevticheskaya effektivnost’ «Semaksa 1%» pri razlichnyh formah ostrogo narusheniya mozgovogo krovoobrashcheniya. Spravochnik vracha obshchej praktiki. 2015; (2): 41–47. Russian.
  56. Gusev EI, Skvorcova VI, CHukanova EI. Semax v profilaktike progressirovaniya i razvitiya obostrenij u bol’nyh s discirkulyatornoj encefalopatiej. Lechenie nervnyh i psihicheskih zabolevanij. 2005; (2): 35–40. Russian.
  57. Ivanova NE. Rezul’taty primeneniya preparata Semax pri kognitivnyh narusheniyah v ostrom periode ishemicheskogo insul’ta i pri hronicheskoj ishemii mozga. Effektivnaya farmakoterapiya. 2012; (2): 2–8. Russian.
  58. Gusev EI, Martynov M.Y, Kostenko EV, Petrova LV, Bobyreva SN. Vliyanie primeneniya semaksa i vremeni nachala reabilitacionnyh meropriyatij na dinamiku soderzhaniya v krovi nejrotroficheskogo faktora golovnogo mozga, vosstanovlenie dvigatel’nyh narushenij i funkcional’noj aktivnosti u bol’nyh, perenesshih ishemicheskij insul’t. ZHurnal nevrologii i psihiatrii im. C. C. Korsakova. 2018 (3): 64–70. Russian.
  59. Kocyubinskaya YV, Kazakov AV, Safonova Vliyanie Semaksa na emocional’noe sostoyanie i kognitivnye processy u bol’nyh ishemicheskim insul’tom v ostrom periode. Medicinskij alfavit. 2019; (24): 38–41.
  60. Rumyanceva SA, Silina EV, Svishcheva SP, SHuchalin OG, Koryukova IV, Eliseev EV. Kompleksnaya nejroprotekciya u bol’nyh s sosudistoj patologiej mozga. RMZH. 2010; (17): 1124. Russian.
  61. Saver JL. Target brain: neuroprotection and neurorestoration in ischemic stroke. Therapies that target the brain in stroke patients will increasingly complement and enhance traditional vasoterapeutics. Rev Neurol Dis. 2010; 7 (Suppl 1): S14–21.